[go: up one dir, main page]

Paul et al., 2019 - Google Patents

Novel mannitol-based small molecules for inhibiting aggregation of α-synuclein amyloids in Parkinson's disease

Paul et al., 2019

View HTML
Document ID
7929644714748024832
Author
Paul A
Zhang B
Mohapatra S
Li G
Li Y
Gazit E
Segal D
Publication year
Publication venue
Frontiers in molecular biosciences

External Links

Snippet

The aggregation of the amyloidogenic protein α-synuclein (α-Syn) into toxic oligomers and mature fibrils is the major pathological hallmark of Parkinson's disease (PD). Small molecules that inhibit α-Syn aggregation thus may be useful therapeutics for PD. Mannitol …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A61K47/48023—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound
    • A61K47/48061—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound the modifying agent being a heterocyclic compound

Similar Documents

Publication Publication Date Title
Paul et al. Novel mannitol-based small molecules for inhibiting aggregation of α-synuclein amyloids in Parkinson's disease
Wu et al. Sequestration of copper from β-amyloid promotes selective lysis by cyclen-hybrid cleavage agents
González-Lizárraga et al. Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species
Gorantla et al. Molecular cobalt (II) complexes for tau polymerization in Alzheimer’s disease
Rana et al. Cu and Zn interactions with Aβ peptides: consequence of coordination on aggregation and formation of neurotoxic soluble Aβ oligomers
Belluti et al. Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010–2012)
Rajasekhar et al. A high affinity red fluorescence and colorimetric probe for amyloid β aggregates
Chen et al. An edaravone-guided design of a rhodamine-based turn-on fluorescent probe for detecting hydroxyl radicals in living systems
Masuda et al. Small molecule inhibitors of α-synuclein filament assembly
Lee et al. Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzheimer’s disease
He et al. Methionine oxidation of amyloid peptides by peroxovanadium complexes: inhibition of fibril formation through a distinct mechanism
Ahmed et al. Foldamers reveal and validate therapeutic targets associated with toxic α-synuclein self-assembly
Ramesh et al. Rationally designed molecules synergistically modulate multifaceted Aβ toxicity, microglial activation, and neuroinflammation
Li et al. A Newly Synthesized Rhamnoside Derivative Alleviates Alzheimer’s Amyloid‐β‐Induced Oxidative Stress, Mitochondrial Dysfunction, and Cell Senescence through Upregulating SIRT3
Pithadia et al. Reactivity of diphenylpropynone derivatives toward metal-associated amyloid-β species
Hadrovic et al. Molecular lysine tweezers counteract aberrant protein aggregation
Wilhelm et al. Protein oligomerization induced by oleic acid at the solid–liquid interface–equine lysozyme cytotoxic complexes
Jamasbi et al. Phosphorylation of a full length amyloid-β peptide modulates its amyloid aggregation, cell binding and neurotoxic properties
Bahramikia et al. Inhibition of human islet amyloid polypeptide or amylin aggregation by two manganese-salen derivatives
Qiang et al. Autofluorescence of MDA-modified proteins as an in vitro and in vivo probe in oxidative stress analysis
Sheynis et al. Aggregation modulators interfere with membrane interactions of β2-microglobulin fibrils
Paul et al. Naphthoquinone–Dopamine Hybrids Inhibit α‐Synuclein Aggregation, Disrupt Preformed Fibrils, and Attenuate Aggregate‐Induced Toxicity
Kumar et al. Fluorescent turn-on anthracene-based aluminum (iii) sensor for a therapeutic study in alzheimer’s disease model of drosophila
Gorantla et al. Cobalt-based metal complexes prevent Repeat Tau aggregation and nontoxic to neuronal cells
Yu et al. Neuroprotective peptide–macrocycle conjugates reveal complex structure–activity relationships in their interactions with amyloid β